Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.52, read 2026-11-03
Ethical does not pass the values gate
Price337.52 USD
Fair value222.36
Ethical score10.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup295.96+14.0% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation295.96+14.0% to today ✓Markup gives way to Accumulation while volume is distributing
2026-08-25Read Markup298.58+13.0% to today ✓Distribution gives way to Markup after a 65% rise in 8 weeks
2026-07-02Read Distribution181.34+86.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Charles River Laboratories holds its Markup at $337.52. The statistical read favours the sellers, held for 56 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 56 days
Price at the screen
$337.52
Valuation
N/A trailing · 27.61 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.34
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
36.02%
Below 33%
Interest-bearing debt is 36.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.90%
Below 33%
Cash held in interest-bearing accounts and securities is 2.9% of assets, under the one-third limit.
Pass
Receivables
10.27%
Below 49%
Money owed to the company is 10.3% of assets, under the 49% limit.
Pass
Revenue purity
0.12%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Charles River Laboratories's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRL's ethical verdict changes
Today CRL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $222.36 fair value estimate, weak competitive moat.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 51.8% above the base estimate.
Where our models see it going: fair-value estimate $222.36, with a range of $168.76 to $255.71, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Drug testing labs fail on value and ethics
Picture a busy lab running safety tests on new medicines while the parent company posts losses and piles up debt. Charles River provides those essential research models and non-clinical services yet the numbers show revenue growth of just 1 percent, a negative 5 percent profit margin and negative 6 percent return on equity.
We pass because the shares trade 23 percent above our fair value estimate at 18 times forward earnings with a weak moat and an ethical screen failure on the debt ratio. Analyst targets sit higher but that does not change the weak growth and poor returns on capital.
High debt adds real downside if drug development spending slows or clients cut budgets. The low growth and negative margins point to structural pressure rather than a temporary dip. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRL trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$351.87-2.1%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$359.41+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$359.41+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$359.41-4.4%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$376.10+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$376.10+8.9%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$345.37+15.1%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$300.02+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$300.02-2.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 45% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209.
2026-10-18Markup$306.24+3.5%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it buy, with a mean price target of $209.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
